{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:14:41Z","timestamp":1783440881372,"version":"3.54.6"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T00:00:00Z","timestamp":1724716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2023NSFSC1696"],"award-info":[{"award-number":["2023NSFSC1696"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11096-024-01784-0","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T16:02:33Z","timestamp":1724774553000},"page":"1419-1426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Post-marketing pharmacovigilance study of inclisiran: mining and analyzing adverse event data from the FDA Adverse Event Reporting System database"],"prefix":"10.1007","volume":"46","author":[{"given":"Dan","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaozhi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6616-5305","authenticated-orcid":false,"given":"Lei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,27]]},"reference":[{"issue":"25","key":"1784_CR1","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","volume":"82","author":"GA Mensah","year":"2023","unstructured":"Mensah GA, Fuster V, Murray CJL, et al. Global burden of cardiovascular diseases and risks, 1990\u20132022. J Am Coll Cardiol. 2023;82(25):2350\u2013473. https:\/\/doi.org\/10.1016\/j.jacc.2023.11.007.","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"1784_CR2","doi-asserted-by":"publisher","first-page":"6377","DOI":"10.3390\/jcm11216377","volume":"11","author":"T Liu","year":"2022","unstructured":"Liu T, Zhao D, Qi Y. Global trends in the epidemiology and management of dyslipidemia. J Clin Med. 2022;11(21):6377. https:\/\/doi.org\/10.3390\/jcm11216377.","journal-title":"J Clin Med"},{"issue":"5","key":"1784_CR3","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.3390\/biomedicines10051090","volume":"10","author":"E Dayar","year":"2022","unstructured":"Dayar E, Pechanova O. Targeted strategy in lipid-lowering therapy. Biomedicines. 2022;10(5):1090\u2013107. https:\/\/doi.org\/10.3390\/biomedicines10051090.","journal-title":"Biomedicines"},{"issue":"9","key":"1784_CR4","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.jacc.2020.12.058","volume":"77","author":"RS Wright","year":"2021","unstructured":"Wright RS, Ray KK, Raal FJ, et al. Pooled patient-level analysis of inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis. J Am Coll Cardiol. 2021;77(9):1182\u201393. https:\/\/doi.org\/10.1016\/j.jacc.2020.12.058.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1784_CR5","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","volume":"16","author":"MK Cheeley","year":"2022","unstructured":"Cheeley MK, Saseen JJ, Agarwala A, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol. 2022;16(4):361\u201375. https:\/\/doi.org\/10.1016\/j.jacl.2022.05.068.","journal-title":"J Clin Lipidol"},{"issue":"9","key":"1784_CR6","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/jcph.2045","volume":"62","author":"KW Smith","year":"2022","unstructured":"Smith KW, White CM. Inclisiran: a novel small interfering RNA drug for low-density lipoprotein reduction. J Clin Pharmacol. 2022;62(9):1079\u201385. https:\/\/doi.org\/10.1002\/jcph.2045.","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"1784_CR7","doi-asserted-by":"publisher","first-page":"6858","DOI":"10.3390\/ijms24076858","volume":"24","author":"A Dec","year":"2023","unstructured":"Dec A, Niemiec A, Wojciechowska E, et al. Inclisiran\u2014a revolutionary addition to a cholesterol-lowering therapy. Int J Mol Sci. 2023;24(7):6858\u201376. https:\/\/doi.org\/10.3390\/ijms24076858.","journal-title":"Int J Mol Sci"},{"issue":"16","key":"1784_CR8","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.7759\/cureus.63078","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319. https:\/\/doi.org\/10.7759\/cureus.63078.","journal-title":"N Engl J Med"},{"issue":"1","key":"1784_CR9","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2337\/dc18-1491","volume":"42","author":"LA Leiter","year":"2019","unstructured":"Leiter LA, Teoh H, Kallend D, et al. Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status: the ORION-1 randomized clinical trial. Diabetes Care. 2019;42(1):173\u20136. https:\/\/doi.org\/10.2337\/dc18-1491.","journal-title":"Diabetes Care"},{"issue":"48","key":"1784_CR10","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","volume":"43","author":"KK Ray","year":"2022","unstructured":"Ray KK, Kallend D, Leiter LA, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022;43(48):5047\u201357. https:\/\/doi.org\/10.1093\/eurheartj\/ehac615.","journal-title":"Eur Heart J"},{"issue":"2","key":"1784_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","volume":"44","author":"KK Ray","year":"2023","unstructured":"Ray KK, Raal FJ, Kallend DG, et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023;44(2):129\u201338. https:\/\/doi.org\/10.1093\/eurheartj\/ehac594.","journal-title":"Eur Heart J"},{"issue":"2","key":"1784_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","volume":"11","author":"KK Ray","year":"2023","unstructured":"Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11(2):109\u201319. https:\/\/doi.org\/10.1016\/S2213-8587(22)00353-9.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"1784_CR13","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.7759\/cureus.63078","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med. 2017;376(15):1430\u201340. https:\/\/doi.org\/10.7759\/cureus.63078.","journal-title":"N Engl J Med"},{"key":"1784_CR14","unstructured":"FDA. FDA adverse event reporting system (FAERS) quarterly data extract files. 2023; https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html. Accessed 12 July 2024."},{"issue":"12","key":"1784_CR15","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s40264-018-0706-7","volume":"41","author":"C Tieu","year":"2018","unstructured":"Tieu C, Breder CD. A critical evaluation of safety signal analysis using algorithmic standardized MedDRA queries. Drug Saf. 2018;41(12):1375\u201385. https:\/\/doi.org\/10.1007\/s40264-018-0706-7.","journal-title":"Drug Saf"},{"issue":"5","key":"1784_CR16","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1007\/s43441-020-00130-6","volume":"54","author":"O Lagerlund","year":"2020","unstructured":"Lagerlund O, Strese S, Fladvad M, et al. WHO Drug: a global, validated and updated dictionary for medicinal information. Ther Innov Regul Sci. 2020;54(5):1116\u201322. https:\/\/doi.org\/10.1007\/s43441-020-00130-6.","journal-title":"Ther Innov Regul Sci"},{"issue":"7","key":"1784_CR17","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048.","journal-title":"Int J Med Sci"},{"issue":"3","key":"1784_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s11096-024-01713-1","volume":"46","author":"Y Oka","year":"2024","unstructured":"Oka Y, Matsumoto J, Takeda T, et al. Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance study. Int J Clin Pharm. 2024;46(3):745\u201350. https:\/\/doi.org\/10.1007\/s11096-024-01713-1.","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"1784_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJW Evans","year":"2001","unstructured":"Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136. https:\/\/doi.org\/10.1002\/pds.677.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"1784_CR20","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1001\/jamacardio.2019.3502","volume":"4","author":"KK Ray","year":"2019","unstructured":"Ray KK, Stoekenbroek RM, Kallend D, et al. Effect of 1 or 2 doses of inclisiran on low-density lipoprotein cholesterol levels:one-year follow-up of the ORION-1 randomized clinical trial. JAMA Cardiol. 2019;4(11):1067\u201375. https:\/\/doi.org\/10.1001\/jamacardio.2019.3502.","journal-title":"JAMA Cardiol"},{"issue":"2","key":"1784_CR21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jacl.2022.01.001","volume":"16","author":"D Kallend","year":"2022","unstructured":"Kallend D, Stoekenbroek R, He YL, et al. Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. J Clin Lipidol. 2022;16(2):208\u201319. https:\/\/doi.org\/10.1016\/j.jacl.2022.01.001.","journal-title":"J Clin Lipidol"},{"issue":"1","key":"1784_CR22","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","volume":"95","author":"RS Wright","year":"2020","unstructured":"Wright RS, Collins MG, Stoekenbroek RM, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran:an analysis of the ORION-7 and ORION-1 studies. Mayo Clin Proc. 2020;95(1):77\u201389. https:\/\/doi.org\/10.1016\/j.mayocp.2019.08.021.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"1784_CR23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1124\/dmd.121.000428","volume":"50","author":"R McDougall","year":"2022","unstructured":"McDougall R, Ramsden D, Agarwal S, et al. The nonclinical disposition and pharmacokinetic\/pharmacodynamic properties of N-acetylgalactosamine-conjugated small interfering RNA are highly predictable and build confidence in translation to human. Drug Metab Dispos. 2022;50(6):781\u201397. https:\/\/doi.org\/10.1124\/dmd.121.000428.","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"1784_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11883-016-0562-9","volume":"18","author":"R Plakogiannis","year":"2016","unstructured":"Plakogiannis R, Arif SA. Women versus men: is there equal benefit and safety from statins? Curr Atheroscler Rep. 2016;18(6):1\u20135. https:\/\/doi.org\/10.1007\/s11883-016-0562-9.","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"1784_CR25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/pharmaceutics15020323","volume":"15","author":"\u0141 Wo\u0142owiec","year":"2023","unstructured":"Wo\u0142owiec \u0141, Osiak J, Wo\u0142owiec A, et al. Inclisiran\u2014safety and effectiveness of small interfering RNA in inhibition of PCSK-9. Pharmaceutics. 2023;15(2):323\u201339. https:\/\/doi.org\/10.3390\/pharmaceutics15020323.","journal-title":"Pharmaceutics"},{"key":"1784_CR26","unstructured":"ClinicalTrials. Gov. ORION-8 (NCT03814187). https:\/\/www.clinicaltrials.gov\/study\/NCT03814. Accessed 14 July 2023"},{"issue":"8_Supplement","key":"1784_CR27","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/S0735-1097(23)02070-3","volume":"81","author":"RS Wright","year":"2023","unstructured":"Wright RS, Koenig W, Landmesser U, et al. Pooled safety analysis of inclisiran in 3576 patients with approximately 10,000 person-years of exposure from 7 trials. J Am Coll Cardiol. 2023;81(8_Supplement):1626.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1784_CR28","doi-asserted-by":"publisher","first-page":"113957","DOI":"10.1016\/j.biopha.2022.113957","volume":"156","author":"G Grze\u015bk","year":"2022","unstructured":"Grze\u015bk G, Dorota B, Wo\u0142owiec \u0141, et al. Safety of PCSK9 inhibitors. Biomed Pharmacother. 2022;156(11):113957\u201365. https:\/\/doi.org\/10.1016\/j.biopha.2022.113957.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1784_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1139\/cjpp-2023-0223","volume":"102","author":"OE Imaralu","year":"2023","unstructured":"Imaralu OE, Aluganti Narasimhulu C, Singal PK, et al. Role of proprotein convertase subtilisin\/kexin type 9 (PCSK9) in diabetic complications. Can J Physiol Pharmacol. 2023;102(1):14\u201325. https:\/\/doi.org\/10.1139\/cjpp-2023-0223.","journal-title":"Can J Physiol Pharmacol"},{"issue":"2","key":"1784_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S2213-8587(16)30396-5","volume":"5","author":"AF Schmidt","year":"2017","unstructured":"Schmidt AF, Swerdlow DI, Holmes MV, et al. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomization study. Lancet Diabetes Endocrinol. 2017;5(2):97\u2013105. https:\/\/doi.org\/10.1016\/S2213-8587(16)30396-5.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"1784_CR31","doi-asserted-by":"publisher","first-page":"e30942","DOI":"10.7759\/cureus.30942","volume":"14","author":"R Shahid","year":"2022","unstructured":"Shahid R, Naik SS, Ramphall S, et al. Neurocognitive impairment in cardiovascular disease patients taking statins versus proprotein convertase subtilisin\/kexin type 9 (pcsk9) inhibitors: a systematic review. Cureus. 2022;14(10):e30942. https:\/\/doi.org\/10.7759\/cureus.30942.","journal-title":"Cureus"},{"key":"1784_CR32","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1500858.","journal-title":"N Engl J Med"},{"issue":"16","key":"1784_CR33","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1501031.","journal-title":"N Engl J Med"},{"issue":"7","key":"1784_CR34","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jacc.2022.05.041","volume":"80","author":"DB Rosoff","year":"2022","unstructured":"Rosoff DB, Bell AS, Jung J, et al. Mendelian randomization study of PCSK9 and HMG-CoA reductase inhibition and cognitive function. J Am Coll Cardiol. 2022;80(7):653\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2022.05.041.","journal-title":"J Am Coll Cardiol"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-024-01784-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-024-01784-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T02:09:46Z","timestamp":1732068586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-024-01784-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1784"],"URL":"https:\/\/doi.org\/10.1007\/s11096-024-01784-0","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,27]]},"assertion":[{"value":"21 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}